Work

A randomized, double-blind phase II study of pembrolizumab versus placebo in patients with head and neck cancers at high risk for recurrence or low-volume residual disease: The PATHWay Study.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.tps6095

Authors: Joshua Bauml, Theodore Karrison, Everett E. Vokes, Roger B. Cohen, Jonas A. De Souza, Charu Aggarwal, Vassiliki Saloura, Nishant Agrawal, Nabil F. Saba, Corey J. Langer, Tanguy Y. Seiwert

Institutions: University of Pennsylvania, University of Chicago, Abramson Cancer Center, University of Chicago Medical Center, Johns Hopkins University, Winship Cancer Institute

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890225410

Cites:

Cited by: 6

Related to: 10